HDAC6 and ovarian carcinoma: Moreover, Lin et al. used CRISPR-Cas9 to study the knock-out of several cancer targets suggested that HDAC6 had no anti-cancer activity in several cancer cell lines, although ovarian cancer cells were not tested in this study [31].